Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Immunomodulating Activity of DW-116, A New Quinolone Antibiotic

  • Moon, Eun-Yi (Central Research Laboratories of Dong-Wha Pharm. Ind. Co. Ltd.) ;
  • Choi, Chung-Ha (Central Research Laboratories of Dong-Wha Pharm. Ind. Co. Ltd.) ;
  • Pyo, Suh-Kneung (College of Pharmacy, Sungkyunkwan University) ;
  • Chung, Yong-Ho (Central Research Laboratories of Dong-Wha Pharm. Ind. Co. Ltd.) ;
  • Yoon, Sung-June (Central Research Laboratories of Dong-Wha Pharm. Ind. Co. Ltd.) ;
  • Lee, Dug-Keun (Central Research Laboratories of Dong-Wha Pharm. Ind. Co. Ltd.)
  • Published : 1998.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

DW-116, [1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1-piperazinyl)-1,4-dihydro-4-oxoquino-line-3-carboxylic acid hydrochloride}, is a new quinolone antibiotic with a broad antibacterial spectrum against G(+) and G(-) bacteria. DW-116 was evaluated for the immunomodulating activities, which is one of the efforts to investigate the mechanism of action related to the good in vivo antibacterial efficacy. The results of in vitro studies revealed there was no statistically significant increase in B and T lymphocyte proliferation. But the results of in vivo studies showed that the number of plaque forming cells (PFC), the amount of polyclonal antibodies and delayed-type hypersensitivity (DTH) were significantly increased after the repeat administration with 12 and 60 mg/kg of DW-116. Taken together, these results proposed that immunostimulting effect of DW-116 could be one of the action mechanisms for demonstrating in vivo antibacterial activities under these experimental conditions.

Keywords

References

  1. Immunology v.14 Further impronement in the plague thchniques for detecting single antibody forming cells Cunningham;A.J.;Szenberg;A.
  2. 35th Intersci. Conf. Antimicrob. Agents Chemother. (Sept. 17-20;Sanfrancisco) Abst. F194 Efficacy of DW-116;a novel synthesiaed quinolone;for treatment of respiratory tract infections (RTI) and urinary tract infection (UTIEfficacy of DW-116;a novel synthesiaed quinolone;for treatment of respiratory tract infections (RTI) and urinary tract infection (UTI) Han;K.O.;Chung;Y.H.;Yoon;S.J.;Lee;D.K.;Choi;K.H.;Choi;E.C.Yang;S.I.;Gong;J.Y.
  3. 35th Intersci. Conf. Antimicrob. Agents Chemother. (Sept. 17-20;Sanfrancisco) Abst.F193 vitro and in vivo activity of DW-116;a new quinolone antibiotic Han;K.O.;Hang;Y.H.;Lee;W.Y.;Chung;Y.H.;Yoon;S.J.;Lee;D.K.
  4. 35th Intersci. Conf. Antimicrob. Agents Chemother. (Sept. 17-20;San Francisco) Abst. F195 Efficacy of DW-116;a new fluoroquinolone;for therapy of experimental thigh infection Han;K.O.;Hang;Y.H.;Lee;W.Y.;Chung;Y.H.;Yoon;S.J.;Lee;D.K;
  5. J. Appl. Pharmac. v.5 vitro and in vivo antibacterial activity of DW-116;a new quinlone actibiotic Hwang;Y.H.;Han;K.O.;Lee;J.;Yang;H.B.;Chung;Y.H.;Yoon;S.J.;Lee;D.K.
  6. 35th Intersci. Conf. Antimicrob. Agents Chemother(Sept. 17-20;San Francisco)Abst. F197 DW-116;a novel antibacterial quinolone:Toxicological studies kwon;H.J.;Moon;E.Y.;Hwang;H.S.;Chung;Y.H.;Yoon;S.J.;Lee;D.K.;Cho;D.H.;Han;H.M.;Sunwoo;Y.;Ha;G.W.;Oh;H.Y.
  7. Drugs v.49 Pharmacokinetic study of new quinolone;DW-116 Lee;D.K.
  8. 35th Intersci. Conf. Antimicrob. Agents Chemother. (Sept. 17-20;San Francisco) Abst. F196 The pharmacokinetic studies of DW-116 Lee;W.Y;Hwang;Y.H.;Yoon;S.J.;Lee;D.K.
  9. Adv. Immunol. v.40 Biological activities residing in the Fc region of immunoglobulin Maorgan;E.L.;Weigle;W.O.
  10. J. Immunol. Method. v.45 A simple and effective methods to assess murine delayed type htpersensitivity to proteins Titus;R.G.;Chiller;J.M.
  11. Trend Pharm. Sci. v.5 Drugs that increase delayed type hypersensitivity reactions Turk;J.L.;Parker;D.
  12. Methods in Enzymology vol.7 Immunochemical technique Vunakis;H.V.;Langone;J.J.
  13. Clin. Exp. Immunol. v.71 Augmentation of DTH to high dose SRBC by CsA in the mouse:influence of drug disage and route of administration and analysis of spleen cell populations Webster;L.M.;Thompson;A.W.